<SEC-DOCUMENT>0001641172-25-015654.txt : 20250618
<SEC-HEADER>0001641172-25-015654.hdr.sgml : 20250618
<ACCEPTANCE-DATETIME>20250618172955
ACCESSION NUMBER:		0001641172-25-015654
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250617
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250618
DATE AS OF CHANGE:		20250618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		251057959

	BUSINESS ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:PCSA="http://processapharmaceuticals.co/20250617">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_PCSA_processapharmaceuticals.co_20250617 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20250617_20250617 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000004" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20250617.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-17</xbrli:startDate>
        <xbrli:endDate>2025-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20250617__20250617_z4d12BPslGCi"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_907_edei--DocumentPeriodEndDate_c20250617__20250617_zSK7oVIMfE91"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 17, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <span style="background-color: white"><span id="xdx_900_edei--EntityFileNumber_c20250617__20250617_zIILOQcWEfAh"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000011" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="border-bottom: black 1pt solid; font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span><span><span id="xdx_90B_edei--EntityRegistrantName_c20250617__20250617_zVCCp3rVKEwh"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000012" name="dei:EntityRegistrantName">PROCESSA PHARMACEUTICALS,
INC.</ix:nonNumeric></span></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as Specified in its Charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span><span><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250617__20250617_zcJ7fG9pltO9"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20250617__20250617_zKl5f77feUgh"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000014" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or Other Jurisdiction of <br/>
    Incorporation or Organization)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer <br/>
    Identification Number)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span id="xdx_905_edei--EntityAddressAddressLine1_c20250617__20250617_zab85kwhtdZi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000015" name="dei:EntityAddressAddressLine1">601
    21<sup>st</sup> Street</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span><span><span id="xdx_901_edei--EntityAddressAddressLine2_c20250617__20250617_z2DnJD61Cig2"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
    300</ix:nonNumeric></span></span></span></span></b><b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_900_edei--EntityAddressCityOrTown_c20250617__20250617_zydJ4cRcxh7l"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000017" name="dei:EntityAddressCityOrTown">Vero
    Beach</ix:nonNumeric></span></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20250617__20250617_z0PRoOplIJHh"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000018" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></span></b><b>
    <span id="xdx_908_edei--EntityAddressPostalZipCode_c20250617__20250617_z6rgFg4TJbz7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000019" name="dei:EntityAddressPostalZipCode">32960</ix:nonNumeric></span></b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of Principal Executive Offices, Including Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_907_edei--CityAreaCode_c20250617__20250617_zdPDoesQXsWd"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000020" name="dei:CityAreaCode">(772)</ix:nonNumeric></span></span>
    <span><span id="xdx_90D_edei--LocalPhoneNumber_c20250617__20250617_zNHb4lxSFKfg"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000021" name="dei:LocalPhoneNumber">453-2899</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
    Telephone Number, Including Area Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_909_edei--WrittenCommunications_c20250617__20250617_zBG4EIikSASj"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--SolicitingMaterial_c20250617__20250617_zvh3tWjQLYlk"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--PreCommencementTenderOffer_c20250617__20250617_zfHahmWVYcce"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20250617__20250617_zsHQySsoYxHa"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20250617__20250617_zSk1uHjigqt4"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000026" name="dei:Security12bTitle">Common
    stock: Par value $.0001</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20250617__20250617_zWeennt5ONYc"><ix:nonNumeric contextRef="AsOf2025-06-17" id="Fact000027" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20250617__20250617_z2jGEV70j8o9"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250617__20250617_zPTVq0JjeOI"><ix:nonNumeric contextRef="AsOf2025-06-17" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2025, <span style="background-color: white">Processa Pharmaceuticals, Inc. (the &#8220;Company&#8221;) </span>entered into securities
purchase agreements (the &#8220;Securities Purchase Agreement&#8221;) with accredited investors pursuant to which the Company sold,
in a best efforts registered public offering (the &#8220;Offering&#8221;), (i) 14,310,000 shares (the &#8220;Shares&#8221;) of the
Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), (ii) Pre-Funded Warrants to purchase up
to 13,690,000 shares of common stock in lieu of shares of common stock (the &#8220;Pre-Funded Warrants&#8221;); and (iii) Common Warrants
to purchase up to 28,000,000 shares of common stock (the &#8220;Common Warrants&#8221;). We sold one share of our common stock
and accompanying Common Warrant <span>at a combined price of $0.25 per Share, and a Pre-Funded Warrant
and accompanying Common Warrant at a combined price of $0.2499 per share.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Warrants have an exercise price of $0.25 per share, are immediately exercisable and expire five years after their original
issuance. <span style="background-color: white">The Pre-Funded Warrants have an exercise price of $0.0001, are immediately exercisable
and will remain exercisable until exercised in full.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) <span style="background-color: white">acted as the Company&#8217;s
exclusive placement agent in the Offering. The Company has agreed to pay the Placement Agent </span>a cash fee equal to 7.0% of the gross
proceeds raised in the Offering. The Company has also agreed to pay the Placement Agent a non-accountable expense allowance of up to
$50,000, reimburse the placement agent for its legal fees and expenses in an amount of up to $100,000, and for its clearing expenses
in the amount of $15,950. In addition, the Company issued to the Placement Agent warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase 1,120,000 shares of our common stock at an exercise price equal $0.3125.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering closed on June 18, 2025. The gross proceeds to the Company from the Offering were approximately $6.3 million (excluding any
proceeds that may be received upon the exercise of the Common Warrants), before deducting the Placement Agent fees and other Offering
expenses payable by the Company. The Company anticipates using the net proceeds from the Offering to continue the Phase 2 clinical trial
of NGC-Cap and for working capital and other general corporate purposes. The Securities Purchase Agreement provides that, subject to
certain exceptions, the Company agreed not to effect or enter into an agreement to effect any issuance by the Company or any of its subsidiaries
of shares of Common Stock or Common Stock equivalents for a period of sixty (60)&#160;days and will not directly or indirectly offer
to sell, sell, grant any option to sell or otherwise dispose of shares of its Common Stock or any securities convertible into, exercisable
or exchangeable for its shares of Common Stock in any &#8220;at-the-market,&#8221; continuous equity, equity lines, or variable rate
transaction, for a period of six (6) months after the Closing Date of the Offering, provided that the foregoing shall not&#160;apply,
following the ninety (90) day anniversary of the Closing Date, to an equity line of credit and an &#8220;at-the-market&#8221;
offering in which the Placement Agent is the sales agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
securities were offered and sold pursuant to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-287997) previously
filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) and declared effective on June 17, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The foregoing summaries of the terms
of the Securities Purchase Agreement, Common Warrants, Pre-Funded Warrants, and Placement Agent Warrants are subject to, and qualified
in their entirety by, such documents attached hereto as Exhibits 10.1, 4.1, 4.2, and 4.3 respectively, and are incorporated herein by
reference. The provisions of the Securities Purchase Agreement, including the representations and warranties contained therein, are not
for the benefit of any party other than the parties to such agreement or as stated therein and are not intended as a document for investors
and the public to obtain factual information about the current state of affairs of the parties to the documents and agreements. Rather,
investors and the public should look to other disclosures contained in the Company&#8217;s filings with the Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01 Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached hereto
and furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Common Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form of Pre-Funded Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Securities Purchase Agreement, dated June 17, 2025, by and between Processa Pharmaceuticals, Inc. and each of the Purchasers (as defined therein).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press release by Processa Pharmaceuticals, dated June 17, 2025.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized, on June 18, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESSA
    PHARMACEUTICALS, INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Ng</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LK4bKLI3HSriFBkivpYtk+LWjLTq9kn+pXVDDIGQ3HtyhZiILW10jQzXVZ7BGZu2Vg4hxwoZTYHeke72CfiZ401bx8q4Yf2BKXkGPTOfysLfB+dTWywTkPMwWoTxDGSUyBiWBxF89ZRMpUs0TqsalCnhxNSyRqe4Hz+cVUeGmn5IuiBbTSaBaCpH+Q2xjGI40lO9iO8WsiwVwWSoQGyZHq13rTuH5kvCusbGx9mR/nfwAcHQSks= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>processa
pharmaceuticals, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: _______, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the date
that is the five (5) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, the date that is
the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from
Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Agreement</U>&rdquo;
means the securities purchase agreement, dated as of June 17, 2025 , by and between the Company and each of the purchasers signatory
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-287997). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Ac</U>t&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 1 State Street, 30th Floor, New York, NY 10004 and an email address of sjones@continentalstock.com, and any successor transfer
agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date
on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any
Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$</B>0.25, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance or the resale of the Warrant Shares by the Holder, then this Warrant may also be
exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) </FONT></TD>
    <TD STYLE="width: 0.1in">= </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed
    and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined
    in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day or (ii) the Bid Price of the
    Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the
    Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
    hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of
    &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B) </FONT></TD>
    <TD STYLE="width: 0.1in">= </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
    </FONT></TD>
    <TD>= </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the
&ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares
subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of
the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant
Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds
such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains
outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date
of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior
to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the
Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the
Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section
2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day
after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person in which the Company is not
the surviving entity (other than a reincorporation in a different state, a transaction for changing the Company&rsquo;s name, or a similar
transaction pursuant to which the surviving company remains a public company), (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&rsquo;s assets
in one or a series of related transactions (which, for the avoidance of doubt, shall not include such transactions that do not require
approval of the Company&rsquo;s stockholders), (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of more than 50% of the voting power of the common
equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the voting power of the common equity of the Company, other than in a transaction pursuant to which the other Person or group
of Persons&rsquo; combined market value is $100 million greater than the Company&rsquo;s market value as of the date this Warrant is
executed, and the transaction results in the acquisition of more than 50% of the voting power of the common equity of the Company, or,
notwithstanding anything to the contrary, in the event of a Fundamental Transaction other than one in which a Successor Entity (as defined
below) in which a publicly traded corporation (i) whose stock is quoted or listed for trading on an Eligible Market (as defined below)
and (ii) that has a market capitalization of at least $100 million, that assumes a Holder&rsquo;s Warrant such that the Warrant shall
be exercisable for the publicly traded common stock of such Successor Entity (and further, these exceptions shall only survive one transaction
after the date of execution of this Warrant) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section 2(f) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(f) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date
of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder,
as described below, an amount of consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion
of this Warrant on the date of consummation of such Fundamental Transaction, provided, however, that, if the Fundamental Transaction
is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be
entitled to receive from the Company or any Successor Entity as of the date of consummation of such Fundamental Transaction the same
type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant,
that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether
that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice
to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders
of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock
will be deemed to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental
Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes
Option Pricing Model obtained from the &ldquo;<U>OV</U>&rdquo; function on Bloomberg determined as of the day of consummation of the
applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined
utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time
equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and
(E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within
five Trading Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved
by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant that is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price that applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to
such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and that is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. As used herein &ldquo;Eligible
Market&rdquo; means the NYSE American, the NYSE, The NASDAQ Capital Market, The NASDAQ Global Market, The NASDAQ Global Select Market,
the New York Stock Exchange, the OTCQB or the OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (unless such information that would be in the notice is set forth in a document filed with the Commission,
in which case no additional notice need be provided) stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board
of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 601 21st Street, Suite 300 Vero Beach, FL 32960, Attention: George Ng<B>,</B> email
address: gng@processapharmaceuticals.com, or such other email address or address as the Company may specify for such purposes by notice
to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing
and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail
address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall
be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail
at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after
the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on
a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>processa
    pharmaceuticals, inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">processa
    pharmaceuticals, inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:_______________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:________________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRE-FUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>processa
pharmaceuticals, inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: ____ __, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its
assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised
in full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Processa Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of June 17, 2025, by and between the Company and each of
the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-287997). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Ac</U>t&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 1 State Street, 30th Floor, New York, NY 10004 and an email address of sjones@continentalstock.com, and any successor transfer
agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other pre-funded Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date
on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any
Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any
circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be
$0.0001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day or (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close
of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder;
and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the
Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days
comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of
delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m.
(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement,
the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise
Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by
its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be [4.99%][9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise
of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the
Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none double; font-family: Times New Roman, Times, Serif; font-size: 10pt">c) </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person in which the Company is not the surviving entity (other
than a reincorporation in a different state, a transaction for changing the Company&rsquo;s name, or a similar transaction pursuant to
which the surviving company remains a public company), (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment,
transfer, conveyance or other disposition of all or substantially all of the Company&rsquo;s assets in one or a series of related transactions
(which, for the avoidance of doubt, shall not include such transactions that do not require approval of the Company&rsquo;s stockholders),
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed
pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of more than 50% of the voting power of the common equity of the Company, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power
of the common equity of the Company, other than in a transaction pursuant to which the other Person or group of Persons&rsquo; combined
market value is $100 million greater than the Company&rsquo;s market value as of the date this Warrant is executed, and the transaction
results in the acquisition of more than 50% of the voting power of the common equity of the Company, or, notwithstanding anything to
the contrary, in the event of a Fundamental Transaction other than one in which a Successor Entity (as defined below) in which a publicly
traded corporation (i) whose stock is quoted or listed for trading on an Eligible Market (as defined below) and (ii) that has a market
capitalization of at least $100 million, that assumes a Holder&rsquo;s Warrant such that the Warrant shall be exercisable for the publicly
traded common stock of such Successor Entity (and further, these exceptions shall only survive one transaction after the date of execution
of this Warrant) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder
shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(f) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(f) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other
Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant that is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price that applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior
to the consummation of such Fundamental Transaction), and that is reasonably satisfactory in form and substance to the Holder. Upon the
occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after
the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein. As used herein &ldquo;Eligible Market&rdquo; means the NYSE American, the NYSE, The NASDAQ Capital Market, The
NASDAQ Global Market, The NASDAQ Global Select Market, the New York Stock Exchange, the OTCQB or the OTCQX (or any successors to any
of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter
specified, a notice (unless such information that would be in the notice is set forth in a document filed with the Commission, in which
case no additional notice need be provided) stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. <FONT STYLE="text-decoration-style: double">Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. </FONT>The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original issue date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 601 21st Street, Suite 300 Vero Beach, FL 32960, Attention: George Ng<B>,</B> email
address: gng@processapharmaceuticals.com, or such other email address or address as the Company may specify for such purposes by notice
to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing
and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail
address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall
be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail
at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after
the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on
a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>processa
    pharmaceuticals, inc.</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">processa pharmaceuticals, inc. </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set
forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration-style: double">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration-style: double">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:________________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_________________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>processa
pharmaceuticals, inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: _______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
Date: _______, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or
its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00
p.m. (New York City time) on June 17, 2030 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from Processa Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement,
by and between the Company and H.C. Wainwright &amp; Co., LLC, dated as of May 27, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the securities purchase agreement, dated as of June 17, 2025, by and between the Company and each of the purchasers
signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-287997).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Ac</U>t&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 1 State Street, 30th Floor, New York, NY 10004 and an email address of sjones@continentalstock.com, and any successor transfer
agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date
on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion
of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any
Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$</B>0.3125, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance or the resale of the Warrant Shares by the Holder, then this Warrant may also be
exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT>
  =</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section
2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior
to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day or (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close
of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT> =</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the Exercise Price of this Warrant, as adjusted hereunder;
and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT> =</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number
of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the
&ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares
subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of
the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant
Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds
such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains
outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed
in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date
of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior
to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the
Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the
Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section
2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day
after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise, other than cash (including, without limitation, any distribution of stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person in which the Company is not
the surviving entity (other than a reincorporation in a different state, a transaction for changing the Company&rsquo;s name, or a similar
transaction pursuant to which the surviving company remains a public company), (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&rsquo;s assets
in one or a series of related transactions (which, for the avoidance of doubt, shall not include such transactions that do not require
approval of the Company&rsquo;s stockholders), (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of more than 50% of the voting power of the common
equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the voting power of the common equity of the Company, other than in a transaction pursuant to which the other Person or group
of Persons&rsquo; combined market value is $100 million greater than the Company&rsquo;s market value as of the date this Warrant is
executed, and the transaction results in the acquisition of more than 50% of the voting power of the common equity of the Company, or,
notwithstanding anything to the contrary, in the event of a Fundamental Transaction other than one in which a Successor Entity (as defined
below) in which a publicly traded corporation (i) whose stock is quoted or listed for trading on an Eligible Market (as defined below)
and (ii) that has a market capitalization of at least $100 million, that assumes a Holder&rsquo;s Warrant such that the Warrant shall
be exercisable for the publicly traded common stock of such Successor Entity (and further, these exceptions shall only survive one transaction
after the date of execution of this Warrant) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section 2(f) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(f) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date
of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder,
as described below, an amount of consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion
of this Warrant on the date of consummation of such Fundamental Transaction, provided, however, that, if the Fundamental Transaction
is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be
entitled to receive from the Company or any Successor Entity as of the date of consummation of such Fundamental Transaction the same
type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant,
that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether
that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice
to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders
of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock
will be deemed to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental
Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes
Option Pricing Model obtained from the &ldquo;<U>OV</U>&rdquo; function on Bloomberg determined as of the day of consummation of the
applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined
utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time
equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and
(E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within
five Trading Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved
by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant that is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price that applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to
such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and that is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. As used herein &ldquo;Eligible
Market&rdquo; means the NYSE American, the NYSE, The NASDAQ Capital Market, The NASDAQ Global Market, The NASDAQ Global Select Market,
the New York Stock Exchange, the OTCQB or the OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice (unless such information that would be in the notice is set forth in a document filed with the Commission,
in which case no additional notice need be provided) stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board
of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 601 21st Street, Suite 300 Vero Beach, FL 32960, Attention: George Ng<B>,</B> email address:
gng@processapharmaceuticals.com, or such other email address or address as the Company may specify for such purposes by notice to the
Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail
address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>processa pharmaceuticals, inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">processa
    pharmaceuticals, inc. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 22%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 32%">&nbsp;</TD>
  <TD STYLE="width: 46%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 22%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 32%">&nbsp;</TD>
  <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:_________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:__________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: right; text-indent: -0.5in"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT</FONT>
10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of June 17, 2025, between Processa Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities
Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a
day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to five (5) years
after the initial exercise date, in the form of <U>Exhibit A-1</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Common
Warrant Shares&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Foley &amp; Lardner LLP, with offices located at 1 Independent Drive, Suite 1300, Jacksonville, FL 32202.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, restricted stock units or options or other awards to employees,
officers, directors consultants of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the
non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for
such purpose for services rendered to the Company, provided that such securities issued to consultants, are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the prohibition period in Section 4.12(a) herein, (b) securities upon the exercise or exchange of or conversion
of any Securities issued hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and
any securities upon exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)
securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company,
provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a)
herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business believed by the Company to be synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers
of the Company, in the form of <U>Exhibit C</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $0.25, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase
price per Pre-Funded Warrant shall be the Per Share Purchase Price minus $0.0001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in full, in the
form of <U>Exhibit A-2</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus included in the Registration Statement, as originally filed or as part of any
amendment thereto, or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pricing
Prospectus</U>&rdquo; means (i) the Preliminary Prospectus relating to the Securities that was included in the Registration Statement
immediately prior to 12:00 P.M. (New York City time) on the date hereof and (ii) any free writing prospectus (as defined in the
Securities Act) identified on Schedule A hereto, taken together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-287997 which registers the sale of
the Shares, the Warrants and the Warrant Shares to the Purchasers, and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
462(b) Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities,
which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated
by the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<FONT STYLE="text-underline-style: double">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and/or Pre-Funded Warrants and Common Warrants
purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise
price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Lock-Up Agreement, the Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing
address of 1 State Street, 30<SUP>th</SUP> Floor, New York, NY 10004 and an email address of sjones@continentalstock.com, and any successor
transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE
AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $7,000,000 of Shares and Common Warrants; <U>provided</U>, <U>howeve</U>r,
that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates,
and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially own in
excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares such Purchaser
may elect to purchase Pre-Funded Warrants in lieu of Shares in such manner to result in the same aggregate purchase price being paid
by such Purchaser to the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the
Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of the Securities on the Closing Date. Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus,
the Company may sell up to $7,000,000 of additional Shares and Warrants to purchasers not party to this Agreement, less the aggregate
Subscription Amount pursuant to this Agreement, and will issue to such purchasers such shares of Common Stock and Common Warrants or
Pre-Funded Warrants and Common Warrants in the same form and at the same Per Share Purchase Price. Each Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and a Common Warrant as
determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable
at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely
by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agent, settlement of the Shares shall
occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares
registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement
Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares
to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the
Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the
Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;),
such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively,
the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional required actions
by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement Shares at the Closing, and
the Company shall be deemed unconditionally bound to sell such Pre-Settlement Shares to such Person at the Closing; provided, that the
Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt of the purchase
price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing
shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser
shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall
solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise (as defined in the Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which
may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject
to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date
(as defined in the Warrants) for purposes thereunder, provided that payment of the aggregate Exercise Price (as defined in the Warrants)
(other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead
and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to
such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
a Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such
Purchaser&rsquo;s Shares plus Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants, if applicable, with
an exercise price equal to $0.25, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
as to each Purchaser purchasing Pre-Funded Warrants, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to
a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded Warrant
divided by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
on the date hereof, the duly executed Lock-Up Agreements; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
the Preliminary Prospectus and the Prospectus (which may be delivered electronically in accordance with Rule 172 under the Securities
Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
this Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such Purchaser&rsquo;s Subscription Amount (less the aggregate exercise price of the Pre-Funded Warrants issuable to such Purchaser hereunder,
if applicable), which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>Closing Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a
specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS
AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall
be deemed a part hereof and shall qualify any representation made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Subsidiaries</U>. All Subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them
in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would
not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business or financial condition of the Company and the
Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect
on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;)
and, to the Company&rsquo;s knowledge, no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or
seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as would not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required
pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) application(s) to each applicable
Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (iv)
such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Issuance of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with
the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the
maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the
Registration Statement in conformity with the requirements of the Securities Act, which became effective on June 17, 2025 (the
&ldquo;<U>Effective Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required
to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending
the effectiveness of the Registration Statement or suspending or preventing the use of Preliminary Prospectus or the Prospectus has been
issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission
pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement
and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to
the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading; and the Pricing Prospectus and
the Prospectus and any amendments or supplements thereto, at the time the Pricing Prospectus and the Prospectus, as applicable, or any
amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements
of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was
at the time of the filing of the Registration Statement eligible to use Form S-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule
3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as
of the date hereof. Except as set forth on Schedule 3.1(g), the Company has not issued any capital stock since its most recently filed
periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock
option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant
to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under
the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate
in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set
forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving
any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock
or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company
or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding
securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset
price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar
plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued
in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Pricing Prospectus
and the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared, in all material respects, in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has
had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any material liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed
in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or
made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate,
except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential
treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>,
no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist
with respect to the Company or its Subsidiaries or their respective businesses, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Litigation</U>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of
the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court,
arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an
&ldquo;<U>Action</U>&rdquo;). There are no Actions that (i) adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable decision, have or reasonably be expected
to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the
subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or
any restrictive covenant in favor of any third party, and to the Company&rsquo;s knowledge the continued employment of each such executive
officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company
and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages and hours, except where the failure to be in material compliance would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be
expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Environmental Laws</U>. The Company and its Subsidiaries (i) are in compliance, in all material respects, with all federal, state,
local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water,
groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of
chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental
Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to
conduct their respective businesses as currently conducted; and (iii) are in compliance with all terms and conditions of any such permit,
license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually
or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except
for matters which are not expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all material patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC
Reports and which the failure to so have would have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the
date of this Agreement. except for matters which are not expected to result in a Material Adverse Effect. Neither the Company nor any
Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice
of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except
as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing material infringement by another Person of any of the Intellectual Property
Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of
all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Transactions With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other
than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in material compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002, as amended that are effective as of the date hereof, and any and all applicable rules
and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company
and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company
and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the
Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the
disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed
periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal
control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially
affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Registration Rights</U>. Except as set forth in <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. Except as set forth on <U>Schedule 3.1(w)</U>, the Company is, and
has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance
requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or would become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of
the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes material, non-public information which will not otherwise be disclosed in the
Pricing Prospectus and the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation
in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, and (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof.
The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from
the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the
Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable and accrued expenses
incurred in the ordinary course of business) and excluding any future contingent liabilities associated with the Company&rsquo;s license
agreements currently in effect, (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z)
the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Accountants</U>. The Company&rsquo;s accounting firm is currently Cherry Bekaert LLP. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<FONT STYLE="text-decoration-style: double; color: #000000; letter-spacing: 0pt">Acknowledgment Regarding Purchaser&rsquo;s Trading Activity.
Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(e) and 4.14 hereof), it is understood
and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed,
to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities
issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any
Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing
of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities;
(iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or
indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have
any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.</FONT> <U></U>The
Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during
the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares
deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing
stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted. The Company
acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement
of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under
the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company
or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. <FONT STYLE="letter-spacing: -0.15pt">The properties,
business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws,
rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any
concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the
Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the
Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Cybersecurity</U>. To the Company&rsquo;s knowledge (i)(x) there has been no security breach or other compromise of or relating to
any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data
(including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of
it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not
been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach
or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such
IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate,
have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards
as the Company believes to be appropriate for a Company of its size to maintain and protect its material confidential information and
the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have
implemented backup and disaster recovery technology consistent with industry standards and practices as considered reasonably necessary
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Compliance with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last year were, in compliance
in all material respects with all applicable state, federal and foreign data privacy and security laws and regulations, including, without
limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy
Laws</U>&rdquo;); (ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to
ensure compliance with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice
of its applicable Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and
(iv) applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its
subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy
Laws. &ldquo;<U>Personal Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph,
social security number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally
identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR;
and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection
or analysis of any identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures
made or contained in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the
execution, delivery and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither
the Company nor the Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability
of the Company or the Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy
Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any regulatory request or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any
court or arbitrator or governmental or regulatory authority that imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<FONT STYLE="letter-spacing: -0.15pt"><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s
knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<FONT STYLE="letter-spacing: -0.15pt"><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real
property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall
so certify upon Purchaser&rsquo;s request.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<FONT STYLE="letter-spacing: -0.15pt"><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates
is subject to the Bank Holding Company Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors
of the Federal Reserve System (the &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates
owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or
any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<FONT STYLE="letter-spacing: -0.15pt"><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted
at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively,
the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company or any Subsidiary, threatened.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither
the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the
Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Validity</U>. The execution and delivery of the Transaction Documents to which such Purchaser is a party and the consummation by it
of the transactions contemplated hereby and thereby have been duly and validly authorized by all necessary action on the part of such
Purchaser and no further consent or authorization of such Purchaser or its members (or shareholders) is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 21pt; text-align: justify; text-indent: 51pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Warrant Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to
cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant
to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any
subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available
for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration
statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again
and available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability
of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities
laws). The Company shall use commercially reasonable efforts to keep a registration statement (including the Registration Statement)
registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Furnishing of Information</U>. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired,
the Company covenants to use commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within
the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even
if the Company is not then subject to the reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers
by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including,
without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In addition,
effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any
of their Affiliates on the other hand, shall terminate and be no further force or effect. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the
Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of
the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any
press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law,
in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.
For avoidance of doubt, any public statement or press release of the Company that does not name any Purchaser and includes disclosure
about the transaction consistent with the initial press release and 8-K filing described above shall not require further consent from
any Purchaser. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission
and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser would be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Non-Public Information</U>. Except with respect to the material pricing terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing
to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To
the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates
delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and
agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any
of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the
Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject
to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Use of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale
of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of
the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the
transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a
material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be
liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior
written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim,
damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or other
agreements in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by
periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred.
The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against
the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10
<U>Listing of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and
Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is
necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible.
The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market
and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading
Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company
or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company
or such other established clearing corporation in connection with such electronic transfer. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12
<U>Subsequent Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
From the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)
file any registration statement or any amendment or supplement thereto, other than the Prospectus or filing a registration statement
on Form S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From the date hereof until the six (6) month anniversary of the Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been
issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, after ninety (90) days
after the Closing Date, (x) the entry into and/or issuance of shares of Common Stock pursuant to an equity line of credit shall not be deemed a Variable Rate Transaction,
(y) the issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering pursuant to the Sales Agreement
dated May 21, 2024 between the Company and A.G.P./Alliance Global Partners shall not be deemed a Variable Rate Transaction and (z) the
entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent
shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude
any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13
<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser
by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14
<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Disclosure Schedules (other than as disclosed to its legal and other representatives). N<FONT STYLE="color: windowtext">otwithstanding
the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees
that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any
securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser
shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries,
or any of their respective officers, directors, employees, Affiliates, or agent, including, without limitation, the Placement Agent,
after the issuance of the initial press release as described in Section 4.4. </FONT>Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15
<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16
<FONT STYLE="color: windowtext"><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality
of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required
in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with
the terms, conditions and time periods set forth in the Transaction Documents.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17
<U>Lock-Up Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its commercially reasonable
efforts to seek specific performance of the terms of such Lock-Up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Pricing Prospectus and the
Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares and Pre-Funded
Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case
of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification
or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately impacted
Purchaser (or at least 50.1% in interest of such multiple Purchasers) shall also be required. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
<U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties, and
covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement. This
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the
benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section
5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10 <U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a
&ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they
would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter
declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13 <U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or
election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case
of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject
to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the
Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such
Purchaser&rsquo;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14 <U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in
lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the
Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16 <U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the
extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in
full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own
separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only,
each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the
Purchasers and only represents Placement Agent. The Company has elected to provide all Purchasers with the same terms and
Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the
Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18 <U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or
other amounts are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19 <U>Saturdays,
Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21 <B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PROCESSA PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to (which shall not constitute notice):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">PCSA </FONT>SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory: _________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrant Shares: ___________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744;  9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: __________________ Beneficial Ownership Blocker &#9744;  4.99% or &#9744;  9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: ____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)
the Closing shall occur on the first (1st) Trading Day following the date of this Agreement (or the second (2nd) Trading Day following
the date of this Agreement if this Agreement is signed on a day that is not a Trading Day or after 4:00 p.m. (New York City time) and
before midnight (New York City time) on a Trading Day) and (iii) any condition to Closing contemplated by this Agreement (but prior to
being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate
or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the
Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable)
to such other party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Processa
Pharmaceuticals Announces Pricing of $7 Million Public Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HANOVER,
Md., June 17, 2025 (GLOBE NEWSWIRE) &mdash; Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the &ldquo;Company&rdquo;), a clinical-stage
pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a public offering of 28,000,000
shares of common stock (or pre-funded warrants in lieu thereof), together with common warrants to purchase up to 28,000,000 shares of
common stock at a combined public offering price of $0.25 per share (or pre-funded warrant in lieu thereof) and associated common warrant.
The common warrants will have an exercise price of $0.25 per share, are exercisable upon issuance and will expire five years thereafter.
The closing of the offering is expected to occur on or about June 18, 2025, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company from the offering are expected to be $7 million, before deducting the placement agent&rsquo;s fees and
other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to continue the Phase
2 clinical trial for NCG-Cap, and for working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
registration statement on Form S-1 (File No. 333-287997) relating to the offering was declared effective by the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) on June 17, 2025. The offering is being made only by means of a prospectus forming part of the effective
registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic
copies of the final prospectus, when available, may be obtained on the SEC&rsquo;s website at <U>http://www.sec.gov</U> and may also
be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone
at (212) 856-5711 or e-mail at <U>placements@hcwco.com</U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">This
press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Processa Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy.
Processa&rsquo;s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism
and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology
pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa&rsquo;s strategy is to develop more
effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit our website at <U>www.processapharma.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
contained in this press release regarding matters that are not historical facts are &ldquo;forward-looking statements&rdquo;, including
with respect to the public offering. No assurance can be given that the public offering discussed above will be completed. Because such
statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking
statements. Any forward-looking statements in this statement are based on management&rsquo;s current expectations of future events and
are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements
include, but are not limited to, those risks and uncertainties related to market and other conditions and satisfaction of customary closing
conditions related to the public offering, the intended use of proceeds from the offering as well as those set forth in the Company&rsquo;s
latest Annual Report on Form 10-K, quarterly report on Form 10-Q, registration statement on Form S-1 filed with the SEC and the preliminary
prospectus included therein, and other filings made by the Company from time to time with the SEC. Copies of the registration statement
can be accessed by visiting the SEC website at <U>www.sec.gov</U>. All forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
Lin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925)
683-3218</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>plin@processapharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave
Gentry</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip
Companies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(407)
644-4256</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PCSA@redchip.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K /@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BFEOF"#
M[W7Z"N.^(/CF+P?I:I;J)M5NOEMH>N.VXCT'IW-2Y)*YI3IRJ24(K5ESQ?X[
MT;P;:[KZ7S+IQF*UBY=_?V'N:X>UU3XG>-V%SIR0:#IC',<DB_,P]>02?R J
MYX)^'#FX/B?QBWVS59CYJQ3'*P]\MV)]N@KJ=0\5-(YL])MGFF?Y8FZ;CZJ/
M0>IXK&=3ECS3=EVZG=&$(R]G27-+JWLOZ[L9X4U'5/[5OM'U*\2^DM(T8W*)
MMRQR",?A76UYCX;_ +<\.>,(=.U">TG;5G:62&(9>!54G);OT''3FO3JWA2G
M3A'GZZ_B<^+<'5O#;3Y]W\V%%%%,Y0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#,N+LV5Z[RH?+8##=L5P-EX>-QX
M]N/$^K3QZ@X.+.WB5B(L?=SQV'ZG->FW$(N+:6%C@2(5)],C%>6ZQJ&K^ ?#
M!T^>TA%A*YMX;FVD^<L^>@/(/7Z5YSPN(=2T*FC=_AN_S/2PTURRM9/;5VNO
M4U(O&C>)]=ET+1U:9HB1=3 8B@7.#N/<]@!6EJ.JZ;X7@:.QC-UJ,ORC'S.[
M>G_UA7GLMEJ?@32[;3;"WC@GU.;*6J2F265L?>8_B!7H6BV-GX9LA<:G-'<:
MLZYE<<[/]E?0?SKTZ&#H4Y^T=YOSW_R2]/O..MBJ=).,I));I;?-]3FM$T/Q
M;9^(7\4ZI-:P+(-KV\OSR%#S@8^Z>G?M7J:G?&"1C<.16#;+<:M,M[>*8K.,
M[HXR,;SV./3^=;^3LSCG&<55>M.K5;G966R.2G5=6]3H]OZ['B<":+:^,_'E
MKJEW/'#:K$;)1<2;XRR$GR\'.<XXKH?!WCF?2_#&CV'BM-0?7+FWDFB3[,S2
M31J3CZOMP<?G5CPIIFM6GQ$\2:I?Z(\-EJK1&&5I8V*>6I'S '//M6CK5CJD
MWQ)T#4H-,DFL+*&:.:<2(-IDP 0"<G&.:S-2Z/'6DRQM);17MRL4*S7'DVY)
MME89'F#J#CG')JU<^+-+B%F+=Y+^6]B\^WBLT\QWC_OX[+[FN>M-*U;PWJGB
MCR-.DU"+6)S<VTD;J-C% I23<1@ CJ,\5E>'/!NK>!M3T>^2%M4B32?[/NT@
M8!XG\SS R!B,KGCK[T =>WC?1_LEC-"T\\E\C/!;QQ?O2J\,2IQC!XYJ/_A/
M=#>RM[NV>>[CF@>XQ;Q%VCC0X9F'48/!K$U/0=0G\8:?XGNM&CO+?[)):3V
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M))8UR"3CY=_/3/0=:KC1->U+7_%]Q-IAM8=8TQ(+5GE4[65&7#@'@G.>,@4
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MGPN)[;4K*"W$$MPA5]A.\'!R."<'U% '>Z3K,&KBX$4-Q#);2>7+'<1[&5L
M_CP1R**P_ VD7^C0:A;3/>?V=YP-A%>R!YHTV_,"P)RN>F3THH ZVL[6M&M]
M;L1;7 'R2++&Q4-M=>AP:T:*<9.+NA2BI*S.%N_#U]-K\5QJ%[;[XXOW5WY1
M+CDY4#/'7.:U;73M)L)!([O>7'53)S@^PZ5T;QI(NUT5AZ,,TV."&(YCB1#_
M +*@45*^*E[L9)+T_P CDC@:"ESM7?FV_P RO$LURP>9=D8.53U^M7***RIT
MU!;W;ZG:W<****T$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pcsa-20250617.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+FubP9z5Z8KekhvWB+bSkqfykkYyuTKiQ+urk24T0O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:PCSA="http://processapharmaceuticals.co/20250617" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.co/20250617">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://processapharmaceuticals.co/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250617_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20250617_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pcsa-20250617_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pcsa-20250617_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pcsa-20250617.xsd#Cover" roleURI="http://processapharmaceuticals.co/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.co/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001641172-25-015654-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-015654-xbrl.zip
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MCKU"&BS2:O.&\B6= $Q(3;-68( ^+EKE<.*G+?+!I/"189(-4KA2P1VC/Y7
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MO7]292KSZJ0Z&+(@]!'4R6W6-AP N['='%S08)-"BNGO0_H[->E0QN>(J]]
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MC4>O/7889LGKC 7KVB@B>8UFXVQ1EOAB8?GRS+1X:WG;.#]YA^$=P-N!6W#
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M#&N:)O<(/GS104@&$353RR3#6UF_Y&<+B?, ,AU_">]G)16#GEPEG36'M4#
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MP;'Q6*B@20:=\*"9JX^AIN <T]WPORY\*;"'(;;=SVU-B_:,:Z I?:'IH"S
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M!&O$_4A<3CFKO9@*0VUM (LQ[P)%5^KG\!SP.A#:26Z(I!7"'.4/O%<U:@M
M+2#;2_YDOK%(XW%C$QR2/[I;XSNN1==TEU00O?3Y\0GF^YM%O;GC:^QU(96B
M LWYVQX2OU !(0XBP'X%$N(S;.4H*U0^ .>Q8,.]%^2ODF<2A?587KHB%]&E
M*@ GN=U4("UE..0_M)A9+4++JWH;3)HL.X8P:L.X]'G;:/"4X&".GW2(38&!
M>]Y6]28<)C^']ZGC<8 A7F8T  02(#R\*HMLQE[,G$2]*MM+7N$7AIHM8@WY
M>X1)A&>&  I<DF8\HNI-SA]R%UYN=I-V7ZN2OL-T/7P$K9'AG,G6Q]MNQ+TA
M1#H"C #;(1P,^6X,'^FOP/[XNSE.^K=]G/0NXZ1_V\=)[_V.^-HG/?G(!N&I
MJPI%G?P>+#'*.KVS1%Y;L#S/RJ2B?.H+BR+U*I[P)'.8#&TAE)&#$ML6V=+1
MA>PNL(>\MM**O"QS[A8'MX"#C[L!QWX3P.64#"EJ/E1F>#JO\"CVV<4(DN!U
MO1.(FZU,5?#;@4<HJAAOA!<^:'1A"!-3AS[8<,Z;&%\8<>.?CW2:*:@<YM40
MG;;$"0]LTQ#N^S*7%GR#=U)F!K20A?Z(HR-N$36:[<*Q!)N4(DDYA/UOP\-[
M/)JW^1P64TS&#-;&QF_IP>:CJ;!UC_U>5M0MSF \]":2U&"0@<-@%WE+-SR=
MA9N8_(JH+2HBQ^_]:F\([,"D)VM6>R\LH"&([ RE08)^ 4,<9Y^?%8A#5YBJ
M/?$9M+&U(CQK7"L&/V63<!.TDG$BD@9!)T50>ZE?R.IM\5(;)5*.J";^(@2.
MU29WH$L?MZ3^C?@[W':UR9 IV;'"$.[_ 3<C#'XMO374-W)@\P "E4E3K7=5
M-L-9P?%#+Z'U-K/]*#R,2-,@"#RU+\=;Q<[D:1P5A@Q*YZ1QDX&P!2(3UKA6
M<_[[Q:J@3?&UP^C45N7ZL!DI!&"!Z&:NAO*/=LSH\%TFE?7:MX$^8E7"P_P(
MLI*;A16# =. P9H<,SN-\4C]9?':_$)]ZL325*TP^Y05V@3"P&/8MR>JS(P;
MHK8%7>N:;5&BSNZVN?3"*!'%B10-PI#M&GC X837.!-#30J&V'S@<)"'\W0,
M.5EA@R,YA605&N4U.-4SS 8[UMRY#N\2,Z-05H/[B<O427" IZ-!*H%/XAKI
MOB[=RZ5AVJB);:$;BJ)0AF*="0G<3;E:1D-UWJG?BAF.6]A_"BXE&%(0S]9X
MWL/#$PD/[<_&'9CTY%]\-H*7BM#^RXK$YRT">4'$^9P\!:-KJ7HAP68-R6S@
MD%%SJRO(W/'$2O(FJ<,NQ'V&#M>K4<QB5R#GOAH\'.V1YTY)K0E2J@/]*W:[
ML,29U^00U$ENZDYNA=LIE7#>$>^'^P4%]]IU<&TLRB14,%YS84T(H3DO*]XW
M4<E7FC)04%X/*0/N[*N_J[L $XS]K=H*&<WL)/S>Q.A<<264HV2U;H[]11A3
M14A[4+;%RG9CV@G]-Q<0Y@ _3F"O66X.OWV_#[_=9?CM^WWX[=[OB*]]TI,D
MD:*Z,K_"_M%\O#[S,/3D9N%>34):*>M\]E3L8)U8++"ARXQ:\FKR36EL"4LT
M'G4AB5(BP0RXCJ.+#L*!@(NM;(NY(&Q!3$-\;M(98^DYAR(Y4G^$%;8&:T_(
MMB!B"CDA!3_9*:!9)1FM%5,5J4&\X1FVV"DUT\:GK--6=-PXP?H]:, 7;$DC
M6U31^!<>1)P+)E^$"/4MS^>6^0D/J?.>P2;PR@/J):&BDE76,,GJ# PE]%/!
M%?4A4@FW.K0,[5HCV.$L==^[2>%]] $%O=@F^< \&0BQY/HQ?O,)ZNJ68I3\
M@^&B2R\*JX\+12D.Q5AJ1GYCLC =2W!G<A[EB^0JR7(M:&O$%PE]+>M;4H:4
M9D]UTO*BIV9=BJ-L[U-B%E*;5DV9_<1[F]%DTZHTV5(SLD*<0BB"65(OK$PR
MQ'=(+'$,^+Q.R8_DE8-2>;+:$FW9'MB,;'.AWQFQ8RQA&:I#=WEH+!022H&R
MNDP*J1TD&H ,5COMXH@0%ERUJT9;V0>_TF!T0DVZJJQ.,Y=:1;>[,,3F1XI"
M@EI!K6HWTP[J#S5>1!N#78 -!; 836D;BN]0S3HJ'1$DC%GQ7Z\*7%B3!L5C
M6[J&,G'Z (?-,!<-@;H;2;B_5 Y?SZ+N!D)\/D@W,J_L:SQ","5HG(\']$!?
M"^'(F,4!9L9$#3@L8>JA3T,^@L=,1^"S7C"%I\BNP[J3Y,YF%77[%%H!XIUA
M7@$)B7#?LXK;K7%;/=WG7$H)S_82*P&VH:LJ4?F5L\SY*D,*4IA$QR./A,!A
M&&P@#@Z7]0%)Q&6;B ^)?3K24N@2?+WN#<=/672V9$=NZ*<$G@T;W/'1AZD5
M1O37"]=N8IX;4;/#N2!?_4V3G%(6]<* ZSL128(GD#,($M^4!Y:QSTV2SF=O
MGCC4PER632:ENMKBCX4G92 %5PDP52GO?$T[=:.9-[QTZ0&"X0&V"LBE=V<Z
M"3 1%UG:D$$!152]1P===P]TT?I4IKJ!O_KV'%)AM\6A<@)_:^[=T!V8]&0Z
M%:ZEY&-T@;T>^Z5!2C#KA69N28YY,S&J1TT['FU@R@S!9X.%IT1+,Z$F0A(S
MIG*D7!H)_5I0/ KGAX?)I@Z3F$I>&J[B]7I2RN=<U8U$#PO,U32P8*"<VJJ@
M5EF.33DULUSH%;SM/%WW+85.\U%!YS.O X/KR)ZG9D+(?.^I\K"S)W48\4Q%
M[N 564H-C^E5#LT8]?5UP8$GQEVZ*OR6C#4T!M'"O6F*CE]G(6#"I$:&#,W"
ME>6'VH,(>+( [^EW+'?O]@#0Y@<NJ\'3GS/Y$U;C$\N183I^<=ST&[NJ@B#M
MC)]F[ ]_M<K79'Y61MB302/3PO-3)3?C!B-^&)5>!8LF9C[\C.P UV^U;R7&
M-O/DF,=ZH'3YG:?!T2*FDZ[$XK4ZXS6Q5% TI+W>OC%\>'*T#Q_>8?CPY&@?
M/OP3[(@O,7&=XP.=Y!]62O1$]__WV +LC/3+V7BS&=MX+\6>>0Z>= M#>H<,
MCDBX]RG=[#FO> .9X5" @5F%+@.FR%4W-3D, !FX&]H::/!M2EFVM20@YRVB
M8*A]1I$GU_-6J5$$]P@+=YG-FUJZ6R(6(V2SU)\YTD'J?,8GOYJ(:%6 C0CO
M<X:-4#-2RS2O*V7$.G!I5#<2M7@VW,J9>6PG8/M0@A@Z$M'*EHEO'0I%+Z4>
M/X%5A2LEAJWP26RIUU*;4;;FD!>?)ZF8)%A+XF=1%*HB1[7Z?'O4:$*N!%])
MO#Z;,5L40NQ'HI#!\AI,M(/(=F?JMJR'=8VYO_W5@?9W2+LFG/5ZF5Y(+5/X
M^<OG[T[OSGZZ+PK@:]5K:2J ;6%YZQ;JA1D'1^V'6+BP)N@Y;'00T6?F0P(J
M( (#;J ?!UKL%%GNZJ=8JM6ZCT#]E#%LURL2)#A@]](D=!6;;K6=3:9PH3BH
MHHIJP]&A666%QIW17PM 4(/D?HJ8D 8L&Z)TIT6!?3.X'XMC[P5= )]29%NX
M<U^8&7/%/CR.P;0^>;S?07^2:4V,T1VD8DYGS;E%5_;Q2_H)[@&7[APHB-@&
M^*-X30\B-1[A;N'S 'PJDUO>OUFR2F;6E08W?>D"Y::X1+R/Q0\.80$'H<8W
M@S\IHHI0P7!J\[8BRR"88A_(Z"9#V/U!RIIYEK8S.AX[)L^$ VKDVG.(&LP6
M686#NYQC)%-TW*XI=4&[1+X[/:O=I! :[=+A(:[6A[9=L:TA@.H-Q#%_<,@D
M+TM3L:#,J"N0:\;9%]V5)[J=0H?!]VOGPQR6*+-N(;JUNBJ0XU%J9FQ0$/%E
MPSW@NLA@%_^A1PVOA*T;9B)!V1.E,OVE9F5(-7C,@C;5=Q.B>:CS)!XGG9>X
MU^5_DFE-YG/4Y?[]Z($IDI^2:#RHFW4.UZ<EV"#F"0:<RNJ'Z/\YHO][ IH4
MX_P/:E0RQ:6$5FX^&:PF5C3DJ7@]A^/1:;%N%HP;Z,H_%5_7AGMP,0!==RXW
M%ZB(0@!UA<UT3[RV=X*-K1$<JWRVCPZ/'TF6'%L64%1=:B'*,I7 OE/:76!&
MY/B;_8X-7JV$W9!)_6'@YR4?<K$E1PAU)WV9Q@191;AGW; ')GI)*OEK0[5E
MV-"<@17?<':UPJ#])C I.3V28H?Y9E>T>RWOC_N9I22M/0AMV&7=<^&01*+,
MTRZVR0:=+2,NIA">L(6Z2KC?@.3 RQ4UXF6>!-O(UU=.?,:,1W:AXA"(;\$Z
M\4!='&P(7)KH(A$ZX(V+X#\SCCC02$<48<%([AB?(3087$4HLUC1W8Q')Q?>
M#DG2"LQZ40?,*(,5%(X:F3K<8+81[<5.0;Y^0!B%U'LW3\8C(=/V)2F6<I(6
M3Y<'ZMIGQ>TF[S(D-G$0&BW<:"2 @R,BP@57;%<2FK?TN9-GDZ3J8RGI3EP?
MCC%961D\SN[.T<H^CO!TI:@O4J4S8>,C$92[-2:8_,\1Q#*\NF<D^BNV5O/J
M-FNFIR""=M#4?>^#:=1<Z%9=]<U#Q&J08JFB)4J?IUEP(;DI%(YK 3\BPY%5
M*8%&$%U0965;$RUU':4MLSRXW)>S2?S"3Y1RAQ:*;]I.?-LPHZ:W#2"+_^"B
M!=A_\ @R>_(,^T$A_*)KGW;&,S4,.]3$8ZQH"I;&@=E/N$;Z %]ACFS=8#:;
M_I@4T@@.N>ME8NT_=+#IO7-3E+KC^48)6V5.(>!"N]D/O10[&0OVZS8AZ D!
MAPI0^Z >R; -[-"M^]#(),(<"3M.'B+UWTRN>%_LF\])\QWOTWQWF>8[WI4T
MW[V6^3__M":7EY954!K%1+^0RF36IWXPR=)W2?^1D/2L*.E4W53]+0!\).#8
M6.(F=D6/:TV*T-@4=F"EAJMH$='I0,0P]6S5NEP$ P/%[ NKY'KUS7/PN7(\
M@PT?Z%Q40-$5*2_P-+[':2I!83CGP*3-J.M$;.,<Q+@?"XB(DC9+S&#Q .>N
M5(^ZF\EO:F%!75LR./]IE%EA(S]+.;Z#+HWBQR43I06'-SQ2^;/PQQJ9<27]
MOG_2\W4LJC=V$4*.Z\QR?&$UKXN%)L7A0!C=,\AJO2E490W_@779D</VSS^M
MR6(AF? 7IUJ\:T-[JZHD\EV/)!=?<X#8DU?_Z^$%@MY+QMR_J-K+Z#0%2]:1
MD4X<W%V>I<U-V$W@7?Z2D8ATJYCO@S=\7M9+@^E;IH>TC+L.-.9WV&I<#ZW@
MJ<_#QRHS#JQ3BW446"008P)Z]@$[T<91GDQ-CO]H3$W=.BP[$+7+(14CT0CV
M:0<C!EXM<H#0G- :D^TK"QT[GQ'&^PZ\B"5LL98L'>IJCQ?Y4XC%5PVNC.1"
MG!I;XL$$HT^97W=ZO1JP#=R$?A<TOVR'7PJ^"7IQ"C7'RI'8ZQ3DOTR"%I#_
M%5(TQ^B (S.SH/9AXJ#FR!.7  /1_N&X8JD=H"*LLM+1,8F0U#+'T25*KULJ
M.@(4#B+?PH)AY!#)!]U7XQ%]-\M!V@E7X'ZD&TA8&F/BN,3CEU:>/DE2LF5K
M^H/;,D4?C%EI"1&Z]5SE+7!-B_SG.&'#570Y\6YH&C-X)PI/UJC$!DRQ CZ)
M8#-:&?&-Z4Z&*[)MQ\YNM,8:'@A,!G.V,05M);$>.AQ;^+;![82Y5]-,WR:W
M'KWDEF:)ISH4+TT2P2M/]88\.L+URBB1_I([ZOAR<8 0&VYU?;N-R3K%#W?>
M8C,O*%W=X7I%R;M.*J)#YU"R1QR&Y4)MH6)H:R=!-]KG]''-AIJAQA*L0B..
M\ACHN4O1Q5;9[^R?TBOE)R9<N$6K!@_56/EL:/IAN$40@$P*A:64+\$1^7^+
MQ18+QX(5_X@X4[$A8JF'"5E+@_I,+#O4,6F%I694KN>/'U6-70MX&Z")4$/6
M:.:HC-4F^Q<%87DT]F[\9M SY9_K%]QHU]NED65ZL.-.'# [T%?Q3;-!-,22
MZ\,2JT#&(PHPJ[FH:B40ZML?,['$$XO?RHR;3^+32?,U6D'(%8_=+K%;[TFW
M;(0I2HI*ZTYZ+Z%0#5J0J9E5AK83=CM,"K8J?VN+[<V:D=2M_VRTN*^T=RV1
M1,%[-IQ37X?8)]4V>K8X1:)A]ELN(B=*:->!_A7*K1N+/5CUWJ1V V.NFW%Z
M<'1X_!@-M?=<:8W-G7E KM072R#@\R3@&G-^HG9&HT!>/SI'05^OM$"#E/50
M=57G;*>U'8^&#VX9""BT0<^5!\4D8,YN0O5GPXOX!]6IPL07V33STP>D_G$?
MQJXP$!&-W(>93-*@Q$6D04_D3AUT:JY,#HN8ZIG-#"2;K#J?Z1L'*> C5OT$
MIIR!SJ:*X5)4E&@.2X8\M[?78U&'IJ%@&9&WP7JC[8S+>5U?E9?2S\/:7?$Y
M(="3?0CT+D.@)_L0Z'W>#'_V^?[E1Z[]0VX 8JY_RWWFW^6)D@Z?D1_M-Z&_
MQ#1<7VUOYN+MM["_!N6MMR'4JG\8>@T'F.]S0Q:[?UN+6A423:7&U;@HG'Q8
M]MQ@9LX!MX@F12Q[/[M'&5='ZB\P*&)&H,! \'QE_R6K+$L)>ZLSY)6Q_:S#
M(_XP>E,.KZ]=4)OZW3)U#[HU^T"5[L-V 3J3(-A@5,EC;)#'>J?XM[T=_&UM
M5D3W,S>%>N&XA)T[QL'@:B%&DRXBSJITOYJ57/?>L+M--Z$N$L%M\(W&O!C@
M U"ENZOJ$(QS491@]-KR?*\*U>\ /43DB09FU^FTC'5^]U<,R#-?ZTJX4/?1
MV#_+M":__2:-*==3]!$X.2+)GQM"+ZBED"BDD8;(;G?8)(LFR[T0!/JP&><)
MR#FROJN/:>T]M%?*XOBV?4I@,UL495Y>K@6<LURUZ!S6Z[HQ2Z1C-,UU67VH
ML7:I2K&.!:..\X;_!2HB0:Q/P#*+'ZJ'YN%L9_!^RB6R<KA"('3]48_1IU=,
MC&$AO<TBJU)&]? ]J7E*0C7??>Y==$.1<N/W-ELI5,^;W40)-!#I%/"Z@%CP
M9#DL#@\*(M!T&JP#/B@;T.Z$EZ@Q)G)P\4MM&&2F#0 WT0.!HU (Q8?R@7F<
M!;<@(8C#-!U+4!C%4A&2).3 G)_T6*^&9YE4Q@-2W1A:5OK[BBHYB&A:>0I^
M:QF=2>&"E"1@HY/*2;FVHG72D"1CT8/86QB%M+7L%(>6EMQT_"BW/&,V9PV>
MXSZYC!_0EH3H%?*C4D#<RX<.+*0F>_EGVGM!&QJ-1T,_H<AB6\AXD36%PN1@
MS(#'&B,],3FH, J7MBU3VZ?*AIM!PCZ%Z0+9&K;%/9Y(_.MVHI]A$!K?@Y Z
M>;L5XZAH0M%(K$1CS'%ND!P'N>(Z3;DL1SF[TV[^S+N0^ QWU%D!EHWIHC-E
MIDYU_>D">XX3K3@>#MU#W78T8U96"N)*GR?$K]GX34Q K@*MS+Y$H&0/;B\+
M&[S5:H+ >LN)UEB[8A(+D(5:NH>BY*]])4=6(WQ;"$\.2  H7;B&<'2XSK(L
MDOV(DMJW-#U=8[FXN]FDO9WR)YG6Y,,'L5,Z"IHTSCM1:*]!.[/M@@[4^UMH
M?S[,,#"-!"\>IE.R!N 749D=4JQW^J(1%?]P'',H<DFU?[$2WW"F3:J%R1P8
M5,ITW'1.D"'T*!Q,'GP4AW[68N@6G*!?J3#Q)U/08V6YK"+WT#]>XOJG%^_.
M [-A<O9K=')T_.TWWW[W_<%FZT/>PWBD+T)O<-OSF%5OP4@/2;*MQ<^A'R!]
MOJ\]03VL:G^K>[BA\8BS4+U#G5V8X.BD%!^\>1.>EIO?C [?,9F1DX=MV&,^
M[UR7!3J:BE3S3_#_2;ZNB5);<#KZ9B8)<C'.V2@T>7D-BXU/\9981MU;W<[R
M2K>-6MC0&R/Y08+.2!Y+15/OJ0;5L&WK&["^<=NM.!LHH_7WYQ,^F>CP&!J#
M#-R-FY:]I<I[/ JD#>0&/P$^*QYH7S]]<>Z$\-]MAC29"C1A?BT6,H?ZM4TA
M[!8OI7'FQ@#,]@'$W=4)=LRA_YY]N?!>=B0$C8BLB@HD!D4KD"ZV8RB2)?HU
M385L?DF:5F1W-28WJP4FF8L62X7QY299[BZ +YORLDI6"RRF+KEB6>5=?X-\
MG+Z=02$,%1BR9X68E'_P1$%@8>\6Z;Y"UAV&G> $P961Z:]D[CE6%Y)M,U]S
M 9.]@ZZ&"[ ICN<]44P^=RU..P >W2R=9]%6U[OZNW =H39\PODXEEJ;*5]E
M9B8-L#I]:6#PY37;@#(#KYL91<K"=T?+*.4N>&<^)^E33&!FDF)VVD:RI4Z1
MT!++HVA'D>[R:#+@+-#OL08^%)F%27*NX:C-1_(?JDS[(_!I^D;@"<Q/:W4;
M["'E>I,-X[@>M'9+M[;+#&:%;N_8:U<2"S$8&/\9GP.]W*JO25QHDT)@YB/(
MJM1/<!D$:VF8*;T<KR?7<*6G;0;D$>)UX/[!XV&P.K4M_(^],XZ L-NI6^(0
MW7$-.[ 1)]PA6=71PY.L$0= &4[77;QF-#02H<:F3=N_EUO[@9JT[JT$L&I?
MN:_61 <$9 ^2#+9XCK5D*,G&NEZ4C+REQJQ5$XO^\. (Z+4L3>H\2 T.4'<?
ME!YYO=H0FJ!*>!O/HQ;T!DO=DF3%:Q_=>=]/'/#6U6?I=>3RQX(ZB"THER(W
M'-S1%E;4U.IS/7\!$"XY-4L/MFX^4R@KF;0T$@RGL/=V_B33ZDYH6W+YX3ZY
M?)?)Y8?[Y/)^"]]%P"+/NU0 &]/H8.Z_)092HK^2H, I=V=XSB6UG\(.AQ]M
M LZ.1QYR%G^62HO<6$E08^8+<:X?UV=+2ZL;6>'"8][#\>-EA-FODT(;PBGJ
MUGB^XDTK$>#_WZ/GW\)37Q@\C^F\]>(8;U^>/O<=Y3U<Z:N8+^RNY?)3=A?)
MRKEA+"P"&M?1SV5.*;[GKG%QO^0M8WR S7<9K&MG:"/+'XA?3FEOONE";NIW
M0Y96%(0C!-==H/7:5>YOWW^G OU*<SKGF$-K<10I[8/C[__V[7 )BHZ3BO71
M9Y<6SV#_K1"QTJ,'$8MWOP^^BOG"/BB*3]D'SS!XXR2?A>>4*WRVGRY#%0CP
ME6MU2#Q0G;*M38]CH7X<"'4WSOGLYT[ME"0B72!<#PS;[?TG\J#*RA4K:DSH
MW, F )^0\UC=1W6N"@Z,/[HHY37W215FC"W]'>?HM((:F=$9]OB_#RQ#A4PF
M:#=#? \VEYPGW-'BJFQL,YI,J4:;:[CC^@'>'U25/*!S[Z:D6@_F9L"[<IQ/
MYLDU(+9ZK?N6?Y;:JL&WTUG<&QIEW+BB%KU6,]@?%S67V&#.ICJ1CTC9")@R
MBIZPX7Y_>HPYN<OY[37KUS!?T*QE^2F:]1?JA_0ZH;B+;4N+ML3F0HG!+AJ(
M2&%[0V.EMFX"A-7/4PZA55P^Q0?H(8CT@5_BQX5]W%V\WSSM.9GODO!2(_Q]
MT,GYW-[ JO/OCCHVBAL+-XO*[>)TT#->Y>8@8J;QBFN#S"/K$*?(NR\AZJ8A
MM=".Z-$X9/;.UO9)H$Y(J0*,3MCIXQ(7)W91.0K%3\O4>D->8"\KKLK\:@!:
MV?&:AL@D!Z>#"DI*)?WZ2.O5#05^PV?Y%9-[=76W\_TBJNKAX8DP>?2[6O_#
M=;7N,>EY6':/U6S.N%^3SQ6C0-P>9 1YEPF!I4?/26E=Z:)=;VJ;QSTA542]
M7GR=> 5>-2\YB39IBUPZ3-+9K<1T?.>&>0LE<8!I1:2A(-4@CA$AKFPVN79)
M+/C[X(>O2!3D[HYM\@<J*OXW"_W)L7WRULD^/J:S\@Y[U3(BZ*W7$?))=*I:
MF:7[HL>L)_8\9D,MHI"5I-J!:<N$A\K)3P5Q7#088S%$EL+WMG$KB3W('I7D
M6P/=Y:6U1V4SP&.14<VC'RV0)[G0 ?']1U5VN6ABUR8@IO13 9MXD:UBYHY#
M \$E@&9._2OGP:J\IHFG?D(IK)]E*Q=!=.URJ=4'FUELQ08>3*=RPMP5-[C.
ML2U#&'V$JCOA;>$%_<DFE,WL,CQ#D[M;D[F=S"\!_SHTB^K[?-;T/ .-Y,5#
MNR*7)F:2%73HO3;D^NB_MVCK:TNT696/V8FU] ;O9S6:G9NH]:&1$S#*;WFF
MJ4P+X*?Y\)KS;,)[LQ%UO< K^54,7354R^NJE_@XP(:6F'/W^/7P$MIB]!"B
M9T"L>"8&CY?M[$X9>X? VYYQ8V<E8,B:H8$0G ('HECC'Q"01.V3]97 A"X%
M,T=N,=UU52'%]2KO6ZZN32T>1+5TSXX[#6MC=+K1+LS:9>0:R:F*D ?"SO'I
M0@B\3#VR>7Y:RC.#=<_@7I9:D91$K7?)M>-)."EZ5A<0'O0SQI65$Y;B!;J%
M8EM 3S3CW(-!$^]NC3@O;_R>=+@@<Y3DF@BSEX5#PUC8NG(^V%8@3,<)1[=5
M;KBOPC*QK^I$^].=WH/#E6G])S+?C_:9[[O,?#_:S<SW/=L ]W6S_\$.MVRJ
M_VK9F>'PX<@NNHL<I*TW6>S)#&-4&D/Q:8QK/9&37/W6"#NJ*@;5*U3C0#N%
M:C3J'B7NX3B6-AR=(K:"-FFU].(2TC(!:GG5LQT"(S92O#%/D-0<ZW5]7YTM
M*G:=B<B)#ST*E07+X1)Y>-;C6)"IOKLN/HH-OSKW2)B8G42F#,MA[?,;PHE>
MV0*W[/62#&A3''S2FW/V/J=&\;WT^GP3@ZAPSNR/^C_K7+'W(>_^LX](9FX$
MAQM*R]#>M[Q'22Z$[4UY:>@3:\5WB@\8.$M[QL.YU.5J@=XZVYSLF!HW&!#!
M@-K(A<ZUZW9="K,.=X.G'0%3T(XO(M]+N*%XGN#F?[!>OU;%,Z890:S,82JH
M )_;5146/%!NSIUV!N]-TW0W'-R .%(:=\+1")"XHEQF,[H+U1E3($3O$?7&
MA(^,(Z%'DK6F!$3LWQ^<%*013"QY7Y27]> @ORK9WK%][%K]X5:!U_[*E3T,
M'MY]XOVL(?E>)-)X:85YI+:04%1EKC(8SN:@BZO-!\&E'GS$TL4;HYXM3$H9
M) H@->6!*S([>RY-].J0RH,%%P-[$RF@Z@PI@6U",DS &8ZKUSH-[HLQ'KE0
MCY;'TV0(O@]_UM>H1+ L.N[WYPJS-4+DI2J%HR7B)',YO?U).9]S6DB96<)-
MNU%M"(Y>&P+YFUVK=>P+#@J*IQBY&TI@.H5I1QE3%T0F!IE[.=#8JMK8)Y?S
M<_52CB>EE%[E%\4J2>-D_(=H2 FCJHIYXD4>V+0(WV@YI;(N;@&1\G [M=/=
MOF+80Z5&NC7IW5J(96-L]XZV\ K!#0H5=U?B=K5T0T+(.$FAZFZL9O0HZ3Q%
M;!N8#64&MRC]K2W_"A][T27=5@S&:1?KV;UPD=@JO;0;];-&L[^<Q*]*#>W\
MR5!%1N>PP3%DM1X:0W?PMEI%Q9X5LOKX*)V;YX43T*(E? <UPT"Z-GG=S4E)
MX0L5K#GZRH%MUQV"<H"X(;B>/3,I!H2#XP&3]J!ET$D"=-Z_#HC#N)U7("^\
M,";5_CWV;5'9XR'H[4%^=6Q!Y95)!1H%78V.=5;<8M'%C/< /-22BU@_;M.1
M$8/5G=#V5W6J[I@%(:U.GW./[P!4$C'KNF.SL#F\MXUV&G"9*7M ;NVP* 5N
MG0T"_PM'-G**!"WB-K=!1_18IS LB!7P#NINCV&@GTNL,'V8:_D@)+]>>;_?
M5BU6=;.Q_5R_:Q0SE10S:7^J^:Y,&RJ%(QZ/YAE,R2.5)O,CJA=81CS1(D3:
MH4E^X BDNVRV#!7@Y;0ZM0N!J4W32,V?:!^ML48\=49C#ICN;O&F280$&Y,M
MN3P0.\$IW1I[0#:9R$DHY)H+.QSB51C O"RQ)M7Z:=K=(NDV(*4<VA)LG>P!
MFS'!07YE0$EC.RY!3-18J4!M[&#F\S+/2C%^J $9_B.\1$R^KAIT/;6Y.D*/
MGH&["I63"&2_Z'3 ZJB#?O+]>V+1;R$,W!P=<R/=%++B@3([1>>HA2]$$,#(
MA,$R;*,L<L[X#,.CY)$$>))%T.7?-&Y^7S2U#1,/&J%T3G=BJ-&[^WTT146A
M6970'?PM4+M*T7[WS=ZIZB'U.X&-&UK&4>B3*WB0(%G+>FJ'%(B%[=[E'>7$
M#6D>I%LP7N5.[2$=ZE,BT?X(=3<'%^ U>K7BLO2EI&7[-@BLC[?/HPX5&V$N
M*&1#TNZT0_BS@]Z69H/7[6G;23VY*K-431[LR4J' K=+=>7LTAF5I3)H!M>1
M8ZSSE2@NE^[#2\#^[EJO31Z04'EZTIR7LT1+H:=E51$+I&*\LX*KB\GCH5QP
MM]NF @4"#2E*BUMG?ETVT]=J',W9./H[PA\<">-GXE]L?]&-O44]"ALUJAC6
MGKG^2C<VL+9PG>FZAXB!KQ0MM0T=(T,?P+-X[6@5N*M]/I7G'VT.N?<&7(CR
MF"X-\I'4U-2=MI8TIJ1R?J5D^;HVRI=Q+FZ'?+Q;".Q[OQ?LUA!(W_JH0^(2
M.DVT/._AX8G7"9=8"A'YC1AW*8LULZX=[4IM;9*N\EK&=PF#NH/Q4H%L='3'
M%A@0_;A%]P[4'*##R])L:G<?VO"I]RFBJ2K^R_-@J%630X%M.M/MD"G_VM,Y
MMU0V-UGJGW:JCT=W>ZSW;-1;G>H4!+MOQ_J7V,&?TU?A\1X =)< H,>["0"Z
M-]+^;YJ0"LB_<SY/G_UX>O[^U?/79^/1J[^#7GH&'YW#K-Z^__GL/#K]Z?SL
M[)>S-^\OHK<O(_@H>H>7GUU\/2MP#TRJNZXK>G1X3 Y)V&2>W9)7S TLYH*$
M8C@ZII=GKEB7&58Y\DC \49;*V#5!0.<"53LX91JBU/"',#,5O6Z)(7?F1>_
M"<=)1DOX13"BJRS!D-Z"2HOTXWCH1OA$D_:9Q,CLL]TT;*F17#Z7_F/X*38+
M*]*:EXV;H-%:<(63QS1O"Z6VP+8FO.C$75F3DFXVK1Q_;&Q8N-_1N#_= V6]
M<.^%DW+XF=<!C2'CR(FN9M=M[AZ'06!:,S]42SSS'+T3_ZQS'S*!,!;-<](H
MMK\ L#)V!63<#0J=FY#U6I,YM0>@82"K_*IQ8Z#[ZB!4:C>M-(J6NST6'S#,
MR"Y3]"FK%$TR[<HEB0;M<ZN]GM65L=:OYZ906) -X0UD@!B!0RF-=0-[$6V&
M% 9L?MW]\-E(0>;//PA)5GC@V$9M$[$ZY],IIH%5S&2@#[Z%3KQP> ,=(#0A
MW!>WUBGN'7O)%LJ2=*3TRYKF7T-9X9<Z\[B6]F5;%5F]$'A-#^?T*[C6#+LU
M295G1"+9S:XAH*@H_4 4<H%<!-P<EA7;:C<*HIF/JXQ;0X?8H"M3)!+<N^5^
MP>' E_,,/L:#0\ OL(;<H91VLW5:O2I=^@5S%_$HO"U^624SS3$>T $GG8(=
MM3%C)?$FO9Y8K'.[!UX7LWSV$5:M &L?"0:0$&D\RD(EYJOV#F7'=GX#_];[
M??IGG"GNTX>T3U]1<PMO9_9/%A02/M((,4<'L1["-9'"-/P-(WS;==B4JX#S
MM2',CK=3A'A'V;''(Y^X':[3^.') $@(I$XZP=O^:)G, KE^%8S#@[5C[=UF
MSJ@$;H.K@)VM+6>0&1OWQ"_<UHWL&P5E:GL>1K5Y\7'7[SC(HL^D=%_#[1PP
M]$)5XY%4[0_>"RFKI]K\B DWAN[J6;C>K?=[]L\X4]RSC[BKHA-B8C1Y81/$
M3^"TG-*.7&_:S9/D0 \4]SMZ<LPV+::WD,\^TI9XDG^V*'T+,_D$>,ETS;#>
MR?2 3\9$6'(:@15C=/\EV C1WQ[\?SZ"9W."+JDM>ID.6 0LQT%C:B6P]Q@$
MR;KH=E<(SK/H)<)RR%6PYZR/ZZ-]%2Q0X))YE4D6_N@80ZRZX'=!M@IC%K'S
M!J^S28.F*+$'; P@G2YKH!S:77Z2;K.>;>VRO>\:ZN[AM6JSL(C(0T5XB </
MG$C$W8:Z>#F\!2?LNX"+ =1C/)P ^5R* <)I*D(91N&<#V)W_,0WNSTMIG!N
M286$0 Z7B_ X&U#!*\>X)3N/T5&FHZ #%XM!S3?7Q@0YL'C3Z_S4MPEK<_O7
M.0B?&7R;LLA8?+3@,AC!\?9$-=*8C!VQ/PJY#:T+WXCW#RH@;O*)-YX:/\%-
MI?X$(9>F[;XJ=.A#6QPPSU"9T;ODAGG.[["1*4Q#"K@QC!VH9X'R:RS?0#?Q
MM!%Y>-AKM622$%GH<FS86('V!;=5:+BO/0FRMB471)DOR?4@ NQV.MN#*;L<
M<=$+?$@LBH\0C>Z%)TD1&(:"WM<K6<.Y6(1*&8$:R'2RF(5YX-?U,X?<O\=_
MLK:?<.A2:2FPZ0F=-S#X# 1:=AX2#HO9E.2>SICV:AV(H %OO3!YRHC\/%EC
M.8WT\,MZ#4-\N(404C#&TI$WL7/HCFV&JW2B=-HGR&TMOHPFRLOA^F4,OR):
ML>6R+:0R\' \>HER,9 ^IE<R\/MM*\B[,2T-.ZK8E:<C<U1 0XH)KG%+-!ZY
M6AL?#M=MB,<8QHRZ=80#P1N#)8*V"BX@W'Y695,\FCU\);<Z88N_BZM!<"]7
M17B<,C>DW_N177Q"SSZ@ZV@Q!J5:UL->Q?C.8-D$QB"3&S*9+#+"]= @UC[\
M(G2#XH%MI&>7MYTZ<"0KWVB.=EHZ:0 T+)#>9!K(). 16 F1;VQ-TYNC-"2:
M'CA@,TG&S=NMOPC=]G+=O1B^57_G^=;:YIWG#8>[&?FMO)$P/D\PG@63V?MV
M7VRF7YK.Y=L]FN,NT1S?[M$<7US\[^=&_X-!G,<<Q/'">N=,/ ;^DP1A001!
MI6=+;JDV-;;:4BC,>CF!LO)"']ZQVW<6&U=90>D1\5U#@'/AD0*?6@X2_I7?
M2]%YL$(ESM%*+LJLV>]VW!!@*T[17:-/5V6&]4VK#!LO>'E'[JGB<<#(,Y2=
MS;K*!P'''SC;#["Y*<$<P(EA$\;CI[&>F70(E-1UDI8KCB-T?(JRB@86QT:<
MN7*=3 <8V*4$BCSR-8UPD^'<'T^,;_ JJYJ63GFN&:-*"R^ZYT@PAZT:Y=SQ
MWJS7-JT?+_C_V[O6IK:Q+?O=5?X/JKYSIW"5H9-TTGET3U<9XB3,)4 !N9FN
MJ:DI8<N@&R.Y)!F:^?5S]O/L(\D\TI#&P??#[0"V=-YG/]9>R]?7JM6QLA>6
ML:=PC/R,Q\ANGJU3S+>99!V2B=WF^:L>:U@JV$Z4<%WTK=MI79[B &OXQ <X
M;;)24CW/-YZ'+I!/URXHPX]2+D'5Y>\\C'H5*I(@424J'J8JCQOL:ZYQX-HM
M]&OG[A"=MM?C8R,\X+GL2V6["0(;!Y^EZX,OZ 2T1W?[$6=_.&E$X>UZ98:)
M(O.93]DSAO<H00">+C-/<UJ3N1=0C $&67])$"\('6E\WP8[%P;9R-=J1MD:
M?;G?(%M.9SP[>G62BH71U-L'QR5HJE'5NJP)!^^I<OK:4#^$FVH<$>!P+ZA\
MY*40;B8N,0KVE)L5LZE:UQ8$((AF >NCB;2A'M\.216^:A@A2/'GD@RWB$J#
M-8%]:6FXRGO_F7#Z7;3;'67UAB-: PP.- 9I>QS')%_,!:;7+:6^H;*0Y5^?
M\P)DK1420FC-D#;6[:2HOI$H*(Q1"WU%O>B_M6*F?HYR@8DY(VUG0FZ/D#IP
MD6)#V@Z;=+;C?.J.IR2?EU(BC8%34Q](2M/4+<Q;FE]PP*86.0OZ?$62\[8)
MB2N.2K=F[_JL_(YLI<=E%;XDGE"*I;,V2QF8@\".IW0!;N& +\K$7\X&>PF?
MC>*JBN%WD:35F[MG+H%H]ZP9O\=36@#F1E&SK;R5 +^YR(LON%KC60K*, K'
M0>RKSY>4B623Z#UO,&SL <%56DZD"G92 ]0';IW>D>/D&(#@E1*CS.)+X06G
M\]7] LX[K1AKX==L>W! A$C&VZR MHV2LN<<;@1 <,.+9.PN"MML.$<0:IN/
M4#PL^'GH?.IS-ZYX@:R-S  D53556G,\ 8W4F;NBC<+UVACHQ+N=0!C^W=;^
M /X(<I\VE/THCH%?-_4DV*S'6Z^)N+Y<15SO,N+Z<A5Q?="[89D[#'?C*T:\
MA@H*<$_6))T.0S1T&-4+ZMO=0\/+$6,,(M)  3<(\C8 '4+]:)P&[TE8>H6^
M$"]8(AKO5Y+[CE&+-477F!BOT'!'DSFI1B/6/=&KI-LI\JG0,E'L1$1X"=^:
M5E/*OP>9ZSC"8TLL9/Q46/N.O^KUN>/TY(O37(4\&^19:U<+_3Y]T0X%QA%0
MN/"3-HQZSPO^7C_<X!33%=L8=PS Z\A_U7!'7S/:KDDW'&[]A%7V%.+U-9@*
M-Q02V_<.Q3X /U0HUHW&&<:>)H2$5&!;MS-%&L^^ZNV05^\Q;7U*6\!_<Z0L
M _(T^,PX/G/#BK\O.:#'U)X!7QM8?/^:CT\X?AB? 0L]$$"E8_)7Q-"!>2)U
M0?] 4\#A[->\R))+E7:9R%ZACWL6UQ,3T=-X?6UDD&P2>%0Y4)BY]4?DBT31
MBH8N5CYY51C$-;CGP7T$.*V)Q;W5""?ZAFVB;T(TN0GGAX1B6L)1I[1@?GX#
MZEF8.0!+U/,O(#\%>N%CU?X)@P,P%"G9PQB=C4$:D D=?-_..!2:%DA@*U$2
MRX2%K#=N0,&HY018#?<#YX1*AX=\JFWSTPX $TC_5\I3B6@>T=SR& &Q^!3J
M@8YC"&,CC#3VL5P_V6W--+PFB^>?(B"R FZ0  K@HSXEY&48%JWH;@<#>QK@
MIH(!.RGT</44RA:1*GH:=!@K%8%ZM!6]HTUE,=;FH[H=>A8K:Q$I,AR>[CQ(
MN41KG!#B,U&5-68<F13Q?-R/3@H@3<^2$W<@)5R."!?R9#Z-SM*2W]VC,F*_
M]#6><ESD\Y/3"JX V@%ADH :&%:Q<'/IPN>CPCVIQ ?5BK+L1FT0PNVW8/20
M95/*><V>YR@]7FMMOCE.+!XT0J 3E^7\C'&!R80IE:EP#!> I#LX^ D:(*/3
MG-"#/I?A!F8$,01AK6\>$)<;T:!ES!8UBVY3S]<HS> SQNX]]*?A" *UDBI1
M5LE:=R#=S)6]<N3+16,N1WJ+%[>L.)Q)9-,+]J] U@*X&*?0A?R<.D15]SR^
M2I4NHF"XE$-"KT7SJ^6-&L8'6<\8JP(Y?VVN/50; ]I2./JPC%(GGE!D/%3,
MK\Z#KU-?J-I8,/ 54PWTY5XQ]VP^2S.VH>4Q,5!;\GD(4<QI.L*XITUT,$K8
M9JAG.<$%ZE>!I^7T?V^_ QJH.P]6-@'3<@884%M/;KK3NF2RG)3>,4P$4'8Z
M*&M+-@SGHA= W-&D*<DJ#RU;PZ#X/#'5VB5%=V(F>N7H#MR<S56)X5VN?*LQ
MS&M8"B-1W4X-F!EF:)GK.D GMT"3?\&5\G\UV"3M.V0<K5J2 RAGP=8AL&NB
M.0@/\LJ-@#NI"/9QQ7CY0-N?,ZPX76QNSE9ZL.M-*9KXNBQ?6&(4.HQ^.;))
M)_LV'4D84N/Q9 'K66**YL,P9&C-XF3A7B?52Y&;=",])85TY2A&5$I"-BWP
M]W4[ICM58%HLX//$\DLMLY%I&R$@%69'E<(%JT.G?P.43*N9;]ZP<%OFJ]0"
M$N. !,>%7+_>@;=7\#U*'CZH(,[7<(&]6L4R[S*6^6H5RWR8VV"9>PI!S-<L
M5>^.S',-8-H\$84P!VWR\?V&+5G@<XB*LL61H"C./"$.3OPH?A*@0.[R5&X>
MN.*A'H\:+\Q-,[@Z9L1,A>!-"#X9/9IL#@$VM.B8<2KLB9IHG!?$LBRP2VH)
M?X0HD$G)-#.+_2YL?HV4I@Y34$JJ%2?-=]!3Y&%[@KMFAR7G6W>,M=^%G)GA
M43=FBQ%&=UPV4WE;$3F3E4Q2RR1E,KV9Q'AL35$N#@W)C(\(2C*]Q <G7$T+
M>E?Z!X]'H<*_MM@ Z@'@CH''2.,28J/C #MMBY:=DK-K6&LI*TY172$&?I)P
M!";MC^]V;O3\<&ZDTHXFIQ_56&T0JD23IO&&8+ QO3\6EY3]@'I-&S!Z@ ]7
M@=DL%77J&%MU\1L,&PN^X_.@YM40?DAP TCRK P:A+?0@K[1M!!9$"T+G=&Q
MCJ9Z+\&<E7[*X-_./P.WF!V P)'%0<"6XP(:L8>C3F+8;+TRS + VX7?SR&F
M^@:(:PVD%!G+VY^!AD6:,542*YO5,:J6$9K8B_I2'>@E&TRRPD17CR\E1DD$
M,)X9GO(O;>O0'P[!KD_<\U.O!-]8?G"G)5/7@2+/G,.'T>D)-@.#C_B%MPF&
M.Z#L\JAP9Z2_Z# FP(KQ)?C):0DPG=$TB0O"?;F;LF"HWS4@P^-+8;<RX)<)
M]^G:9IB5=5U+VDHWB?NQ.0X;T7=T]3RR2_:I,4V3,=ZJWU$7']ED$HW?H2>0
M OB9.].07GTUMW?24^C$7S*_:W&OVWDG8$U+(SA'8L8R_<--]=K/3WKNCY>E
MH4)BRS)ZZ[X3*AC6F4$4?JW,4Y!;(-94#+, :UM.' F^:DT].7Q*EL\A:H(1
M3D,Q"L*G6$=DZ7O8Q&WS(Z] 4@J))(BW31,A/6CC1I5<*VA7R"_*N3,%$Y_N
M :BL 95B?HR56.<E"3.2/;+@)8CD1H3XX?JKMFL3W5.&H#B;+TLFSE*%\L)[
MVXU_V1K]FB#FZU40\RZ#F*\?:1#S8:WYY>_6VO'5UPV"V-,_W(73B]PIC>=<
MAO5QL9?I"F^>9F"#9'J1$!#9X]W;?.4+ELX3834@!S#0%]XZ7!R.&7BY56Y,
MGW>K&P?YYP&^IM7P$8X$/)03?9"$/\^GYW17_-.] R--!S!R)@NY8<KT%W[(
MUNL#KA)P:P'/J";.;5_ULB8IG003AU #"(43,)ID#1J4#R5Z"RQ%Q0,,A<8S
MN!(3!F,29J"0 *O0N@.$#)KA>8N,\!-KP'N=\05W/%LB:X,>:250*Z@DJTA'
M8'1(6!=_IG8P2+1@\!)'@^@#HDUJL5XDV'1.DV[I"3%R@=\CP783\RM]H49[
MTZVB@5I:,"#$3-7@*%PX!XC%6]OL"0C5CX'IO>UWV%&3-27N? CY0R &KL(S
M$4VB_6O(,6_73-Q&RK^8CRAZR5\CA P%L11!2O35P/*Y0!$8<9=,Q@#!'"G!
MJ4%)>!+.*/XE<U+?M@BYP;.BY-6K'(*-G</RR($%&X1= !.AB@+80OBTC(@S
M!;';HR(9IVQ@RHZ.JW77NG5N+'(9NR?R/NZK&&X <X'D-QG/9EOB9I"9\_@Y
MFGFJGYSR8 GU9-E,BU#<4\]+5EZOYA@+!W236ZXDV\'<R6V/#9]!"XZ]RRD@
M!MPJF *^Q)UF4D(*AU<??G&:7[A54-#/L&#[O 0SUQWP55ZSK^*6ZP)G9>T/
MQFAE57$9\26 ^SE8NNU[-,P1+9C! $?##"%7'-]0#G;9JWDW"UN F#B_/,Q:
MEM-=5DF#"YXDT0Q(>(S[Y:-;+\^>]J-G3YX]7T@7,MAXO[&_\>-@RG(5[Z?Y
ML=OM^X*)OV6?\9F('H*5^U53<8N!T!.Z5DN-19 X* CV%W[-&_>BCG)4"P2*
MXJLIG44L%9!F_\): -3GF:;)),!7&WX%4<4CEYB(%G@T!*@%1/SCRRN!-WIU
M@M\!ISE#[Q^)@[C\W5H;.6/Y6J;( %+VU(ILDN!WG6L_&OX!N?AH6U>4H%F1
M4"5?O-9E<P!.MO&81[*JK@X[_/1D%7:XP[##3T]688<'L.:7.9Z/&0P2.'&>
M-[+")G$E.<YZN><NU9*D4+B")VJ-C@YEBTVY:(@HZOGK&.T.\EZP9$UHHKG4
M#WX4Y6/AZ$.6D(L8@AWPZ_JKD,M RD^;[Q:6*'0N@1$X[ = JJ=E+NTB*A</
M*)AQ15<#)+4!,6@ :Q>^,<+-P)>/;Y3A;P%XE^#BR0XY 9@"F4/U"MBZJA$R
MC;-4S%B? ^[%98.,&ZMGT3]SPPG1GI!_BUARDCJ_34E%>ZY?I:&8P"(;J3BY
M(/PP]JE =Z9L/(,B2A2<'R4%.6[PX),BG\]:Z=9F_'4@"2I]*4,1G><,D EX
M_RQ-^BK-MHP]Q0.(U%JVW!(!/^#(UB'"ZML*:;28I*6VTDOP>JEB"#:(6ZG_
M<B9@ /;B^F-=H;;2 :P[P!4)7YYFYWQ192M57EXT4)%!62&]75!2+&A.IQ6W
MHQ3I)5O@ZU:YU>@.:C?J*!X3PS!E#USAA%B\;!3X>-2*]G,2BWJX=!W</:JB
M%J4YCN%=528:/@T(WU,W&)Z<77*5XX;SO8!@'DG@A%7>*%X]WWA^+ZM ,KO:
M<SK9KJV/;72\1:^F=I3?= 0\K3X&H0,BR%J-%RZS &?5$%F9\") @O\15[EY
MA2+7CZH6AJ"V>38QCD"/M;;0""0)15(9L ;%I1D%2%V[P9XF)ZS>21^T-4GG
M"8AW[@:GC#/4\^*-ZV$VSB_@3/KAMWKY?^#]R1((^1BRR^J48%=2I-.L9Q+I
M,> &B(O+,(F2_('3,UVH<V,J'0-51I#Q*#EQ;JNOM/CJTM8T1QJX9-TTJ91+
MLA.PJ:_D*T-C:B%IF8E)W__6IDFY?F5']86-\>5@ &UU8E6D(P9Q+DYFH85C
M^H3KE4H%%PT-?&#D;MUQJ^1LO59[TI3 NN&(LEEW]Z?EPA&E@&):'U6)6EQ+
M7@FU<O"G@%R1]__B\;PIY24C-O\L=61?N2._BO+2QL1M@/6K!EP1FM?$J.2<
MCDLA//%S(QFG. (*QG3=&52N=V,N8\26GR>G;JDDFNE0QP*PO9-\F@+N%KY5
ME/R/\"-"U[. )-6Y $G%O+1H5S2?BDO'K2F:G$@/Q;#F$AOK+%HF"+(L'8M:
MBN86W@W24"P+N+*E?3ZZ^13U#'Y6D ;+;RG^U^J%&)5Y?&@DXRZ9I$:+:<MC
MIQ9TF6LLL=&4;/";!D7GVX[9Q^O47!-)?+J*)-YE)/'I(XTD/OAML,P]1=_^
MQ0KK_EWT%"<3I!2N<<D@DBP(&J35'3NOL/25@^!%PL6ZJ\)=^G%Q*\4B4JEZ
M?XFC39U7:)%JB>!,7^/I)/*&<&8*<42L8\H]QL>^!N/;!C]%_BDSM_150=*[
MP0BN@?"G>!?&05G8C-K;G:'KW__9FJD:R %H%S'?P7'OCN42>+[=J[^LYT5Z
M@F)NS=%L:0UI0'!U(X3KD['[)_3D9!YC_#E!S!W[[>[&@ ?ZOY'<FK/7_P_[
MWY.X5,M4XBR;5Z/G==WPVZ(Q=DKRS*/@O'.A"\/3'S,7>;W@K^G.D3^*\8Z^
ME?! ^Q9\-PJ<V467:M5I"ZN);O'O9J<_LC.-B,!W\M&7]4\S;WF7BW3!$3H
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MYU)&5;[N$?DEGZERR@E.@#1G(5$5HQU*UCC)P4)R2=2&B?#AF!)#>+3F5':
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ME]?>NWY;32GE>2"EX0DFI5! (O,ASS3D6^?32U]92;G&T(V(Y]5I7H!($@G
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M":/#L^I/D/I9K>A1_'Y2%FG&7Y^K2F5%,H6QHEHU./OF/(Z2!AY>1@UL,XX
M,Z9'X'C>/\<14KAS]-MR^NS^^^?A&EX5,'R21\?ZS7A'O5W#J?# \RJ#_\+,
M'S_9VXOFN[/=: =/^O>R^A"]R!J>Q2B21>.;AP/<ZBBKZ9,I['&T\W@4+54"
M\RP*^'M5)]4R*J?T0.=L8GAQ>9&E*I5SRZ:PC9-S7AH,792P!]%IE:19<08_
M6<;F_9&\'N<!S\YF*LW@XWP)VY?GY27^P/EAN#NG<&ZPYW@ [8T9+QIZ=8.[
M2YL>X^; "=>3*ALKHB_<O?FBFIR#+A=-JW(V'+P3;2YZ%RISKT"9@Q.-CE2>
M7()@AN.OYF7%[P^F]J*<S>'@W1DAP>$,A'AKDNW13E*[5)>D>-%F"C4 G/@"
M+EK%&]:Z/:(>>*N&DX)7SV!")TTY^; ;G<(OS0J!1"8*GRD+Q1,(?Q#1"^%]
M<'!&%8$G\SR"+5/_7,#QR^4P5/ .1X6-J:-43;,"""&#T6!!N"\/=L:CW2_/
MDX2[WR%IL;?[^(;EQ2_/Y9"&@WTDHMT(/CK"(V2>1I_=J27?P5-\!:>7I"R%
M],UD>:8OH\IK=8F\!*^E>[&9K5A.RS\[3RX4?3%320$?U_"S%#A@P_>:!M"7
M>__)G=K+.T@>5F@<3*=9GOE2<CC 0ZY)17D'LIY4 Y3A:08Z5P-R&%6LPORM
M.:_*Q=DYB0_X9E8242'=H."N,IP)Z$1-5>8U_;36?P6%*QHOY3.6,1,6._+
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MD!Y=O -*DTHS]).2V=TP)*L'G(HRB>(*6E*$&<<(D$$QKD2KW3 79P#7L>I
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M'6!ED7.N1Z=RCPIO3&;C2R<FM?=8] Y;S([ESUC-[C[/$CXG7"E,=W:5$M3
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M;F*C7"8@[L7T>)5KGTRE)%*J0PX.5>&IQ#Z&F /4O?XXC$N\U!D'G8?4ES*
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ML/*1F(AC>0M^RX,:\/)/"E@R7#&P"@QU3X'/:F/"C!SL$QIZ5>A!ASB"K7A
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M/>]*L+XFCWWI_.I-\OHF>7V3O+[2Y/6+3?+Z1HJM6(HI4FG-E[,JPY$(^!@
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M6IQ<])"0G1X=O#_Z!V'&_'SVR[O7_Q]02P,$%     @ NHO26K"1SX:;3@
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MUZZMYD7FV(VV!) SB9T*-:IV72<QL+Z"4IT2]>R;T"HK^.V,Q2'/3D#E=8-
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M<*; >T=22M:(-OE]=-HS,SB7'+C+Q45LC1CY96Q:5:+'RB!VT?WZB!T:88>
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M$8Z0^& &.ZS%]SAS?4._!Z_X2BAY>6QA?V\;7+C+X,+^WC:Z<$\OQN8O2YI
M'6HMQ%BTJFV-Y<T30]=;U/[M+NG<5?A\M3YL)NMZ^G.CE6_%&B.&A0H%(*4
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ML<+D5QB' 483D\GRZ*A].3QRF0P34>\HQD>C!^V#:Y*;#&N99I+9*?I%C.H
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M8S?*$%';!MT*(6WLUE ZVMWNS>9NSDE4Q4_[O=O8@P>U+Y^24/?=5YY&YU:
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MG^CYV_0O'_T_A:1_,?E?4$L#!!0    ( +J+TEJ:[!,$>QD  ".T   +
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MQF(=.F[ZM2Y-+-U#3M@[H]+=W>VRC[T?,%L)Q<H%2*2/RI6L4BE5=_>>% X
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MAM626&WUNJV;6JRM,J"CI.HC<=7'Y[;6]$&Q,8-I+B@VTQ*I*,]AHA5,P-_
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M(#*>Z.-)X+.TQUYM[!7%"9#"6O:I)US%&VJC6^D@24+R>\,4?%1*F9UJ#'7
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M:8\'F73%UML]+"!75KMD"YY0(3%UE_">S F+X!,[V5R"DK70:@(E&=2#%9P
MU^JSL:TV%+Y\G $C8?8Q#G.PCT4O%DTWEL""RR)0&5=!IIR%(-9"DZTEPD.K
M>Y5C0\Y<$ *' \Q'V(5($A<'ND4UYZ14=4[5F 4P BIO&!]=@X^C0(7U'N&
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MO0?'CI*'ULI\(=C/GH?]#(X=)1>ME8F)?6 _WJH'N?3,0'N-H<A1<M$:B9C
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M4AH*Y'%*.'^?:2:H#O8M!X90R(AK7BNEH4"^3JF:V4[MHY)+,]_L[0S!]A2
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MUXT]X-Y=6WSC?KGWL]HC_P-02P$"% ,4    " "ZB]):+FD\#7:C  !A P0
M"@              @ $     97@Q,"TQ+FAT;5!+ 0(4 Q0    ( +J+TEJ+
MGN(<?4X  '_Z 0 )              "  9ZC  !E>#0M,2YH=&U02P$"% ,4
M    " "ZB]):&/Y"2%%+  #/XP$ "0              @ %"\@  97@T+3(N
M:'1M4$L! A0#%     @ NHO26K"1SX:;3@  R/P!  D              ( !
MNCT! &5X-"TS+FAT;5!+ 0(4 Q0    ( +J+TEHD\#0-: L  #@Y   *
M          "  7R, 0!E>#DY+3$N:'1M4$L! A0#%     @ NHO26IKL$P1[
M&0  ([0   L              ( !#)@! &9O<FTX+6LN:'1M4$L! A0#%
M  @ NHO26KMM)TXU P  # P  !$              ( !L+$! '!C<V$M,C R
M-3 V,3<N>'-D4$L! A0#%     @ NHO26ET7W^?]"@  ?X8  !4
M     ( !%+4! '!C<V$M,C R-3 V,3=?;&%B+GAM;%!+ 0(4 Q0    ( +J+
MTEI^+7KW9P<  /!7   5              "  43  0!P8W-A+3(P,C4P-C$W
>7W!R92YX;6Q02P4&      D "0 3 @  WL<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pcsa-20250617.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2025-06-17</startDate>
            <endDate>2025-06-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-17" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-17" id="Fact000004">0001533743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-17" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-17" id="Fact000010">2025-06-17</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="AsOf2025-06-17" id="Fact000011">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-17" id="Fact000012">PROCESSA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-17" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-17" id="Fact000014">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-17" id="Fact000015">601     21st Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-06-17" id="Fact000016">Suite     300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-17" id="Fact000017">Vero     Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-17" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-17" id="Fact000019">32960</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-17" id="Fact000020">(772)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-17" id="Fact000021">453-2899</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-17" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-17" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-17" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-17" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-06-17" id="Fact000026">Common     stock: Par value $.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-06-17" id="Fact000027">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-06-17" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-17" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROCESSA PHARMACEUTICALS,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601
    21st Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vero
    Beach<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">453-2899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock: Par value $.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.co/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>pcsa-20250617.xsd</File>
    <File>pcsa-20250617_lab.xml</File>
    <File>pcsa-20250617_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>26
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.co/20250617",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20250617.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20250617_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20250617_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://processapharmaceuticals.co/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://processapharmaceuticals.co/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
